Guy A Higgins, Nathalie Breysse, Elijus Undzys, Calvin Kuo, Narges Joharchi, D Richard Derksen, Tao Xin, Methvin Isaac, Malik Slassi
Lacosamide ((R)-2-acetamido-N-benzyl-3-methoxypropionamide; formerly harkoseride, SPM 927; Vimpat), has been recently approved by US and European regulatory authorities for use as add-on therapy for partial-onset seizures in adults. Because a number of anti-epileptic drugs are used to treat conditions beyond epilepsy, including anxiety, in the present study we investigated the anxiolytic potential of lacosamide in a conditioned emotional response (CER) model in rat, and the mouse marble burying assay. In each test lacosamide produced a significant effect consistent with anxiolysis, i...
December 10, 2009: European Journal of Pharmacology